Evidence map›Paper›PMID 37507278›Full record

ArticleClinical oncology (Royal College of Radiologists (Great Britain))2023

The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer.

H Abdel-Aty, L O'Shea, C Amos, L C Brown, E Grist, G Attard, N Clarke, W Cross, C Parker, M Parmar and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical oncology (Royal College of Radiologists (Great Britain)), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Predictive imaging biomarkers on whole-body diffusion-weighted MRI (WB-DWMRI) and [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

H Abdel-AtyDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden Hospital NHS Foundation Trust, London, UK; The Institute of Clinical Trials & Methodology, Medical Research Council Clinical Trials Unit at UCL, London, UK. Electronic address: hoda.abdel-aty@icr.ac.uk.
L O'SheaThe Institute of Clinical Trials & Methodology, Medical Research Council Clinical Trials Unit at UCL, London, UK.
C AmosThe Institute of Clinical Trials & Methodology, Medical Research Council Clinical Trials Unit at UCL, London, UK.
L C BrownThe Institute of Clinical Trials & Methodology, Medical Research Council Clinical Trials Unit at UCL, London, UK.
E GristCancer Institute, University College London, London, UK.
G AttardCancer Institute, University College London, London, UK.
N ClarkeDepartment of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
W CrossDepartment of Urology, St James's University Hospital, Leeds, UK.
C ParkerDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
M ParmarThe Institute of Clinical Trials & Methodology, Medical Research Council Clinical Trials Unit at UCL, London, UK.
N Vas AsDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
N JamesDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
Institute of Cancer Research · GBMRC Clinical Trials Unit at UCL · GBUniversity College London · GBMedical Research Council · GBRoyal Marsden Hospital · GBSalford Royal NHS Foundation Trust · GBSt James's University Hospital · GB

Funding

Medical Research Council MC_UU_00004/01
6 · The paper itself

Abstract

aimsThe forthcoming STAMPEDE2 trial has three comparisons in metastatic hormone-sensitive prostate cancer. We aim to determine clinical practices among STAMPEDE trial investigators for access to imaging and therapeutic choices and explore their interest in participation in STAMPEDE2. MATERIALS AND

methodsThe survey was developed and distributed online to 120 UK STAMPEDE trial sites. Recipients were invited to complete the survey between 16 and 30 May 2022. The survey consisted of 30 questions in five sections on access to stereotactic ablative body radiotherapy (SABR), 177lutetium-prostate-specific membrane antigen-617 (

resultsFrom 58/120 (48%) sites, 64 respondents completed the survey: 55/64 (86%) respondents were interested to participate in SABR, 44/64 (69%) in

conclusionThere is noteworthy disparity in clinical practice across current study sites, however most have expressed an interest in participation in the forthcoming STAMPEDE2 trial.

Indexed as

Prostatic NeoplasmsAndrogen AntagonistsAndrogensDocetaxelHealth Services AccessibilityHumansMagnetic Resonance ImagingMaleNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProstate-Specific AntigenReceptors, AndrogenSurveys and QuestionnairesWhole Body ImagingAndrogen AntagonistsAndrogensDocetaxelProstate-Specific AntigenReceptors, Androgen177lutetium-PSMA-617metastatic hormone-sensitive prostate cancerniraparibpositron emission tomography/computerised tomographyprostate-specific membrane antigenstereotactic ablative body radiotherapy

Identifiers

PMID37507278
PMCPMC7616818
OpenAlexW4385076606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.